Related Experiment Video
Updated: Aug 29, 2026

An Optimized Protocol for Candida albicans Infection in Schmidtea mediterranea to Study Fungal Pathogenesis and Host Defense
Published on: April 17, 2026
Scedosporium species infections and treatments
1Department of Pediatrics, Duke University, Durham, NC 27710, USA. stein022@mc.duke.edu
Abstract:
Scedosporium species are now increasingly isolated from immunocompromised and immunocompetent patients. Unfortunately, Scedosporium species infections are generally resistant to amphotericin B, and S. prolificans strains are particularly resistant to presently-available antifungal agents. Here we review the microbiology, expanding epidemiology, numerous clinical presentations, and diagnostic tools available for Scedosporium species infections. Finally, we detail the available in vitro, animal model, and clinical data on the treatment of Scedosporium species infections with special emphasis on the role of newer antifungal therapies for these recalcitrant infections.
Insights
Scedosporium species infections are challenging due to antifungal resistance, particularly in immunocompromised patients. This review covers diagnosis and treatment, highlighting newer antifungal therapies for these difficult-to-treat infections.
Area of Science:
- Medical Mycology
- Infectious Diseases
Background:
- Scedosporium species are increasingly identified in patient infections.
- These fungi often exhibit resistance to conventional antifungal drugs, notably amphotericin B.
- Scedosporium prolificans presents particular challenges due to its limited susceptibility to existing treatments.
Purpose of the Study:
- To provide a comprehensive overview of Scedosporium species infections.
- To discuss the microbiology, epidemiology, clinical manifestations, and diagnostic approaches.
- To review current and emerging therapeutic strategies for Scedosporium infections.
Main Methods:
- Literature review of Scedosporium species.
- Analysis of microbiological, epidemiological, and clinical data.
- Evaluation of in vitro, animal model, and clinical treatment data.
Main Results:
- Scedosporium infections are becoming more prevalent in diverse patient groups.
- Established antifungal agents show limited efficacy against many Scedosporium species.
- Emerging antifungal therapies show promise for managing these recalcitrant infections.
Conclusions:
- Effective management of Scedosporium infections requires accurate diagnostics and tailored treatment.
- Newer antifungal agents are crucial for addressing the resistance challenges posed by Scedosporium species.
- Further research into novel therapies is warranted for Scedosporium infections.
Related Concept Videos
Fungal Phylum Microsporidia
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Staphylococcal Skin Infections
Fungal Phylum Ascomycota
Cryptococcal Meningitis
Candidiasis